Trial reportRadiation oncology (London, England)2015
Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted MR imaging: a pilot study.
Trial report in Radiation oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trial
- Which is the best timing to assess response after chemoradiation in locally advanced cervical cancer (BRILACC)?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Tumor shrinkage patterns and optimal timing of response assessment during neoadjuvant therapy for breast cancer: a study based on multiparametric MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Development of a Predictive Model for Therapy Response in Advanced-Stage Cervical Cancer Using Apparent Diffusion Coefficient (ADC) Value and Quantitative T2 Tumor on MRI: Correlation with Survivin Expression.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Utility of interim apparent diffusion coefficient value in predicting treatment response among patients with locally advanced cervical cancer treated with radiotherapy.Clinical and translational radiation oncology · 2024Article
- Added-Value of Diffusion-Weighted Imaging (DWI) and Dynamic Contrast-Enhanced (DCE-MRI) Magnetic Resonance Imaging in the Preoperative Assessment of Cervical Cancer.Journal of obstetrics and gynaecology of India · 2022Article
- Diffusion-weighted MRI to detect early response to chemoradiation in cervical cancer: A systematic review and meta-analysis.Gynecologic oncology reports · 2021Review
- Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.European radiology · 2020Article
- Quantitative Magnetic Resonance Imaging for Biological Image-Guided Adaptive Radiotherapy.Frontiers in oncology · 2020Review
- Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy.European radiology · 2019Article
- Cervical cancer apparent diffusion coefficient values during external beam radiotherapy.Physics and imaging in radiation oncology · 2019Article
- The PRICE study: The role of conventional and diffusion-weighted magnetic resonance imaging in assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery.European radiology · 2018Article
- The value of advanced MRI techniques in the assessment of cervical cancer: a review.Insights into imaging · 2017Review
- Role of Functional Magnetic Resonance Imaging Derived Parameters as Imaging Biomarkers and Correlation with Clinicopathological Features in Carcinoma of Uterine Cervix.Journal of clinical and diagnostic research : JCDR · 2017Article
- Apparent diffusion coefficient histogram shape analysis for monitoring early response in patients with advanced cervical cancers undergoing concurrent chemo-radiotherapy.Radiation oncology (London, England) · 2016Article
- Evaluation of the efficacy of chemoradiotherapy in cervical cancer using diffusion-weighted imaging and apparent diffusion coefficient.OncoTargets and therapy · 2016Article
- Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer.Journal of computer assisted tomographyArticle
- Volume Delineation in Cervical Cancer With T2 and Diffusion-weighted MRI: Agreement on Volumes Between Observers.In vivo (Athens, Greece)Article
- Usefulness of Short-Term Imaging and Squamous Cell Carcinoma Antigen to Early Predict Response to Concurrent Chemoradiotherapy in Patients With Cervical Cancer.Cancer control : journal of the Moffitt Cancer CenterArticle
- Role of apparent diffusion coefficient as a biomarker in the evaluation of cervical cancer.The Indian journal of radiology & imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the feasibility of DWI in evaluating early therapeutic response of uterine cervical cancer to concurrent chemoradiation (CCR) and establish optimal time window for early detection of treatment response.
methodsThis was a prospective study and informed consent was obtained from all patients. Thirty-three patients with uterine cervical cancer who received CCR underwent conventional MRI and DWI examinations prior to therapy (base-line) and at 3 days (postT1), 7 days (postT2), 14 days (postT3), 1 month (postT4) and 2 months (postT5) after the therapy initiated. Tumor response was determined by comparing the base-line and postT5 MRI by using RECIST criterion.
resultsPercentage ADC change (γADC) of complete response (CR) group at each follow up time was greater than that of partial response (PR) group, and the differences were significant at postT3 (p = 0.007), postT4 (p = 0.001), and postT5 (p = 0.019). There was positive correlation between γADC at each follow-up time and percentage size reduction at postT5. The day of 14 after the therapy initiated can be considered as the optimal time for monitoring early treatment response of uterine cervical cancer to CCR, and the representative and sensitive index was γADC. With the cut-off value of 35.4%, the sensitivity and specificity for prediction of CR group were 100% and 73.1%, respectively.
conclusionsIt is feasible to use DWI to predict and monitor early treatment response in patients with uterine cervical cancer that undergoing CCR, and optimal time window for early detection of tumor response is the day of 14 after therapy initiated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.